Insider Trading Activity For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Bruce Leicher , SVP of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) reportedly Sold 350 shares of the company’s stock at an average price of 16.6 for a total transaction amount of $5,810.00 SEC Form
Insider Trading History For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Analyst Ratings For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
These are 1 Sell Rating, 4 Hold Ratings, 2 Buy Ratings .
The current consensus rating for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) is Hold (Score: 2.14) with a consensus target price of $16.71 , a potential (2.86% upside)
Analyst Ratings History For Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
- On 8/24/2015 Sanford C. Bernstein Reiterated Rating Buy
- On 6/6/2016 Goldman Sachs Group, Inc. (The) Initiated Coverage of rating Neutral with a price target of $14.00
- On 8/5/2016 Brean Capital Set Price Target of rating Buy with a price target of $19.00
- On 11/3/2016 J P Morgan Chase & Co Reiterated Rating Buy with a price target of $18.00
- On 2/21/2017 Leerink Swann Downgraded rating Outperform to Market Perform with a price target of $18.00 to $18.00
- On 5/3/2017 Aegis Reiterated Rating Hold with a price target of $17.00
- On 5/3/2017 Cowen and Company Reiterated Rating Hold with a price target of $15.00
Recent Trading Activity for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Shares of Momenta Pharmaceuticals, Inc. closed the previous trading session at 16.25 up +0.35 2.20% with 746,780 shares trading hands.